BALPHARMA2024-10-012024-12-31 BALPHARMA2024-10-012024-12-31 BALPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member BALPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member BALPHARMA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524824 BALPHARMA NOTLISTED Bal Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-13 2025-01-23 INR Lakhs Third quarter 17:00:00 17:40:00 2025-02-13 2025-02-13 Not applicable Single segment PHARMACEUTICLES 2024-10-01 2024-12-31 Unaudited Standalone 728852000.00 8197000.00 737049000.00 375507000.00 34953000.00 -43560000.00 148056000.00 50128000.00 23305000.00 136617000.00 725006000.00 12043000.00 0.00 12043000.00 1448000.00 -964000.00 484000.00 0.00 11559000.00 0.00 0.00 0.00 0.00 11559000.00 0.00 11559000.00 0.00 0.00 159209000.00 10 0.73 0.73 0.00 0.00 0.73 0.73 1. The above unaudited financial results of the Company have been reviewed by the audit committee and approved by the Board at their meetings held on 13.02.2025. 2. The Standalone financial results have been prepared in accordance with Companies ( Indian Accounting standards Rules , 2015 (IND AS) prescribed under Section 133 of the Companies Act,2013, read with relevant rules issued thereunder and other recognised accounting practises and policies to the extent applicable. 3. The Commpany has only one reportable segment i.e Phmaraceuticles. 4. The Company has outstnding recoverability of Rs.869.89 Lakhs and Rs.152.23 lakhs from its subsidiaries i.e Lifezen Healthcare Pvt Ltd and Balance Clinics LLP. The said subsidiaries have incurred losses and have negative networth. However the management is confident that with infusion of additional funds and introduction of new brands, renewed marketing and internal restructuring and Companies can be revived and amounts recovered. 5.The Company has not received any intimation with regards to its vendors registration as micro, small and medium enterprises . Accordingly , entire dues to the vendors has been classified as payment to other then MSME's. 6.The Company has filed application with NCLT for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company. 7. Previous period figures have been regrouped/rearranged whereever considered necessary to confirm to the period presentation. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 2207128000.00 19795000.00 2226923000.00 1099841000.00 93006000.00 -54372000.00 435307000.00 129019000.00 65225000.00 410564000.00 2178590000.00 48333000.00 0.00 48333000.00 11609000.00 -4350000.00 7259000.00 0.00 41074000.00 0.00 0.00 0.00 0.00 41074000.00 0.00 41074000.00 0.00 0.00 159209000.00 10 2.58 2.58 0.00 0.00 2.58 2.58 Other Expenses 136617000.00 Other Expenses 410564000.00